Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20).

Trial Profile

Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20).

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2014

At a glance

  • Drugs Insulin glulisine (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 28 Jun 2011 Final results presented in a late-breaking session at the 71st Scientific Sessions of the American Diabetes Association (ADA).
    • 24 Jun 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top